Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Financial Results (May 5, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 5, 2026
Period End
May 5, 2026
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · Apr ’21Apr ’21
  3. Leadership change8-K · May ’25May ’25

Summary

Summary of the 8-K filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported first-quarter 2026 financial results on May 5, 2026, with total revenues of $814.5 milliona, compared with $572.6 million in the prior-year period, a 42% increase.

Net product sales were $811.0 millionb, representing 44% year-over-year growth. INGREZZA net product sales were $656.9 million (20% growth year-over-year), and CRENESSITY net product sales were $153.3 million, versus $14.5 million in the first quarter of 2025. GAAP net income was $197.9 million, or $1.91 per diluted share, compared with $7.9 million, or $0.08 per diluted share, a year earlier.

Non-GAAP net income was $200.5 millionc, or $1.94 per diluted share, versus $71.5 million, or $0.70, in the prior-year period. The company reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion. Full-year GAAP R&D guidance is $1.200 billion to $1.250 billion, and GAAP SG&A guidance is $1.375 billion to $1.400 billion.

The guidance excludes post-close expenses from the pending acquisition of Soleno Therapeutics. Operating expenses rose on higher R&D tied to the osavampator and direclidine Phase 3 programs and on expanded commercial sales teams. Cash, cash equivalents, and marketable securities totaled $2,647.2 milliond at March 31, 2026.

A key corporate development is the definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, a total equity value of $2.9 billion, with closing expected in the second quarter of 2026. The company also initiated a Phase 2 study of NBI-1117570 in schizophrenia and a Phase 1 study of NBIP-'2118, a potential obesity therapy. Investors should weigh the strong top-line growth and reaffirmed INGREZZA guidance against rising operating costs and the integration risks of the Soleno transaction.

Key Highlights

  1. Total revenues of $814.5 million in Q1 2026, up 42% from $572.6 million a year earlier.
  2. Net product sales of $811.0 million, up 44% year-over-year; CRENESSITY contributed $153.3 million versus $14.5 million in Q1 2025.
  3. INGREZZA net product sales of $656.9 million, up 20% year-over-year, with double-digit prescription volume growth partly offset by lower net price.
  4. GAAP diluted EPS of $1.91 versus $0.08; non-GAAP diluted EPS of $1.94 versus $0.70.
  5. Reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion.
  6. Agreed to acquire Soleno Therapeutics for $53.00 per share in cash, a total equity value of $2.9 billion, expected to close in Q2 2026.
  7. Cash, cash equivalents, and marketable securities of $2,647.2 million at March 31, 2026, up from $2,543.4 million at December 31, 2025.

Frequently Asked Questions

  1. What drove the revenue increase in the first quarter of 2026?

    Total revenues rose to $814.5 million from $572.6 million, led by CRENESSITY, which generated $153.3 million versus $14.5 million in the prior-year quarter, and by INGREZZA, which grew to $656.9 million from $545.2 million. The filing cites strong patient demand and approximately 80% reimbursement for dispensed CRENESSITY prescriptions.

  2. Why did operating expenses increase?

    The filing attributes higher R&D expense to an expanded pipeline, including the osavampator Phase 3 program in major depressive disorder and the direclidine Phase 3 program in schizophrenia. SG&A rose due to commercial investment, including expansion of the INGREZZA and CRENESSITY sales teams. Acquired IPR&D expense also increased, to $21.2 million from $0.1 million, due to upfront payments under early-stage license agreements.

  3. What are the key terms of the Soleno Therapeutics acquisition?

    Neurocrine agreed to acquire Soleno Therapeutics for $53.00 per share in cash, a total equity value of $2.9 billion. The acquisition adds VYKAT XR (diazoxide choline), a treatment for hyperphagia in Prader-Willi syndrome, and is expected to close in the second quarter of 2026. Full-year 2026 guidance excludes post-close expenses from the transaction.

  4. What did the company guide for 2026?

    Neurocrine reaffirmed INGREZZA net product sales guidance of $2.7 billion to $2.8 billion. It guided GAAP R&D expense of $1.200 billion to $1.250 billion, GAAP SG&A expense of $1.375 billion to $1.400 billion, and GAAP and non-GAAP IPR&D of $20 million. Non-GAAP guidance excludes stock-based compensation and other items.

  5. What was the impact of the sale of Neurocrine Group Limited?

    The company recognized a pre-tax gain of $28.6 million, net of transaction costs, on the sale of Neurocrine Group Limited in January 2026. Management excludes this gain from non-GAAP net income and operating income.